A Search Service for Abbreviation / Long Form

■ Related PubMed/MEDLINE Info.

[Related PubMed/MEDLINE]
Total Number of Papers: 281
[Display Entries]
100 entries :
      (Publication year, Descending)
100 entries :
      (Publication year, Ascending)
all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation : HSCT
Long Form : hematopoietic SCT
No. Year Title Co-occurring Abbreviation
2015 Clinical significance of pretransplant serum ferritin on the outcome of allogeneic hematopoietic SCT: a prospective cohort study by the Kanto Study Group for Cell Therapy. ---
2015 Efficiency of allogeneic hematopoietic SCT from HLA fully-matched non-sibling relatives: a new prospect of exploiting extended family search. aGvHD, DFS, HORCSCT
2015 Evaluation of pretransplant influenza vaccination in hematopoietic SCT: a randomized prospective study. HI
2015 Focal nodular hyperplasia of the liver: an emerging complication of hematopoietic SCT in children. FNH, HR, MRI, US
2015 Gut microbiota trajectory in pediatric patients undergoing hematopoietic SCT. aGvHD
2015 Haploidentical BMT and post-transplant Cy for severe aplastic anemia: a multicenter retrospective study. CY, SAA
2015 Haploidentical HSCT: a 15-year experience at San Raffaele. ---
2015 Hematopoietic SCT in Iranian children 1991-2012. CI
2015 Identification and validation of biomarkers associated with acute and chronic graft versus host disease. GVHD, GVHR, IL-33
10  2015 Impact of ABO blood group mismatch in alemtuzumab-based reduced-intensity conditioned haematopoietic SCT. HR, RIC
11  2015 Long-term persistence of the immune response to antipneumococcal vaccines after Allo-SCT: 10-year follow-up of the EBMT-IDWP01 trial. IDWP01, PCV
12  2015 Once-daily i.v. BU-based conditioning regimen before allogeneic hematopoietic SCT: a study of influence of GST gene polymorphisms on BU pharmacokinetics and clinical outcomes in Chinese patients. AUC, GST, PK
13  2015 Physiochemical disparity of mismatched HLA class I alloantigens and risk of acute GVHD following HSCT. aGVHD, EMS, HMS
14  2015 Pre-transplant diabetes mellitus is a risk factor for non-relapse mortality, especially infection-related mortality, after allogeneic hematopoietic SCT. CI, DM, HR, NRM
15  2015 Sinusoidal obstruction syndrome/veno-occlusive disease: current situation and perspectives-a position statement from the European Society for Blood and Marrow Transplantation (EBMT). EBMT, SOS/VOD
16  2015 Subsequent malignant neoplasms in pediatric cancer patients treated with and without hematopoietic SCT. SMNs
17  2015 Traffic Light: prognosis-based eligibility for clinical trials of hematopoietic SCT in adults with sickle cell anemia. CSCCD, CWRU-UH, SCA
18  2014 A multicentre UK study of GVHD following DLI: rates of GVHD are high but mortality from GVHD is infrequent. aGVHD
19  2014 Accuracy of self-reported tobacco use status among hematopoietic SCT patients. ---
20  2014 Aerobic exercise capacity at long-term follow-up after paediatric allogeneic haematopoietic SCT. DLCO
21  2014 Allogeneic haematopoietic SCT for natural killer/T-cell lymphoma: a multicentre analysis from the Asia Lymphoma Study Group. NK
22  2014 Analysis of post-transplant chimerism by using a single amplification reaction of 38 Indel polymorphic loci. STRs
23  2014 Challenges and opportunities for HSCT outcome registries: perspective from international HSCT registries experts. ---
24  2014 Clinical guidelines for gynecologic care after hematopoietic SCT. Report from the international consensus project on clinical practice in chronic GVHD. cGVHD
25  2014 Delayed hematopoietic recovery after auto-SCT in patients receiving arsenic trioxide-based therapy for acute promyelocytic leukemia: a multi-center analysis. APL
26  2014 Early CD3+/CD15+ peripheral blood leukocyte chimerism patterns correlate with long-term engraftment in non-malignant hematopoietic SCT. NMDs
27  2014 EBMT risk score can predict the outcome of leukaemia after unmanipulated haploidentical blood and marrow transplantation. EBMT, haplo-EBMT, HBMT, LFS, NRM
28  2014 Fear of recurrence and its impact on quality of life in patients with hematological cancers in the course of allogeneic hematopoietic SCT. FCR, FoP-Q-SF
29  2014 Health status of childhood leukemia survivors who received hematopoietic cell transplantation after BU or TBI: an LEA study. QoL
30  2014 Health-related quality of life of patients with newly diagnosed chronic myeloid leukemia treated with allogeneic hematopoietic SCT versus imatinib. HRQoL, ISD, MCS
31  2014 Hematopoietic SCT for the Black African and non-Black African variants of sickle cell anemia. SCA
32  2014 Hematopoietic SCT in Europe: data and trends in 2012 with special consideration of pediatric transplantation. ---
33  2014 Hematopoietic SCT: a useful treatment for late metachromatic leukodystrophy. ARSA, MLD
34  2014 High prevalence of distress in patients after allogeneic hematopoietic SCT: fear of progression is associated with a younger age. PTSD
35  2014 HLA-haploidentical hematopoietic SCT from collateral related donors without in vitro T-cell depletion for hematological malignancies. cGVHD, CRDs
36  2014 Impact of HLA allele mismatch on the clinical outcome in serologically matched related hematopoietic SCT. NRM
37  2014 Impact of pretransplant body mass index on the clinical outcome after allogeneic hematopoietic SCT. BMI, HR, NRM
38  2014 Long-term outcome of HLA-haploidentical hematopoietic SCT without in vitro T-cell depletion for adult severe aplastic anemia after modified conditioning and supportive therapy. SAA
39  2014 NHANES III equations enhance early detection and mortality prediction of bronchiolitis obliterans syndrome after hematopoietic SCT. BOS, cGVHD, PFT
40  2014 Optimizing drug therapy in pediatric SCT: focus on pharmacokinetics. MPA, PBMTC
41  2014 Outcome of children with high-risk acute myeloid leukemia given autologous or allogeneic hematopoietic cell transplantation in the aieop AML-2002/01 study. allo, auto, CI, DFS, HR
42  2014 Outcome of invasive mechanical ventilation after pediatric allogeneic hematopoietic SCT: results from a prospective, multicenter registry. IMV, PICUs, RRT
43  2014 Pre-transplant MRD predicts outcome following reduced-intensity and myeloablative allogeneic hemopoietic SCT in AML. MA, MFC, MRD
44  2014 Quantitative chimerism: an independent acute leukemia prognosis indicator following allogeneic hematopoietic SCT. AL, CI, HR
45  2014 Reconstitution of regulatory T-cell subsets after allogeneic hematopoietic SCT. ---
46  2014 Risk factors for thrombotic microangiopathy in allogeneic hematopoietic stem cell recipients receiving GVHD prophylaxis with tacrolimus plus MTX or sirolimus. SIR, TA-TMA, TAC, TAC/SIR
47  2014 Salvage therapy with everolimus reduces the severity of treatment-refractory chronic GVHD without impairing disease control: a dual center retrospective analysis. cGVHD
48  2014 Second haematopoietic SCT using HLA-haploidentical donors in patients with relapse of acute leukaemia after a first allogeneic transplantation. NRM
49  2014 Severe weight loss in 3 months after allogeneic hematopoietic SCT was associated with an increased risk of subsequent non-relapse mortality. NRM
50  2014 Sputum cytokine levels in patients undergoing hematopoietic SCT and comparison with healthy subjects and COPD: a pilot study. COPD
51  2014 Systemic lupus erythematosus complicated with thymoma and pure red cell aplasia (PCRA). CR of both complications following thymectomy and allogeneic haematopoietic SCT (HSCT), but persistence of antinuclear antibodies (ANA). ANA, PCRA
52  2014 Thrombomodulin alleviates murine GVHD in association with an increase in the proportion of regulatory T cells in the spleen. rTM
53  2013 Application of machine learning algorithms for clinical predictive modeling: a data-mining approach in SCT. DM, ML
54  2013 Escalating-dose HLA-mismatched DLI is safe for the treatment of leukaemia relapse following alemtuzumab-based myeloablative allo-SCT. ---
55  2013 Experiences of t-PA use in moderate-to-severe hepatic veno-occlusive disease after hematopoietic SCT: is it still reasonable to use t-PA? tPA, VOD
56  2013 Glutathione S-transferase gene variations influence BU pharmacokinetics and outcome of hematopoietic SCT in pediatric patients. GST, PKs
57  2013 Haploidentical hematopoietic SCT increases graft-versus-tumor effect against renal cell carcinoma. GVT, haplo-SCT, HI, RCC
58  2013 Hematopoietic SCT in Europe: data and trends in 2011. ---
59  2013 Human herpes virus 6 reactivation: important predictor for poor outcome after myeloablative, but not non-myeloablative allo-SCT. aGVHD, HHV-6, MA, NMA
60  2013 Human parvoviruses B19, PARV4 and bocavirus in pediatric patients with allogeneic hematopoietic SCT. HBoV, PARV4
61  2013 Impact of being overweight on outcomes of hematopoietic SCT: a meta-analysis. aGVHD, CI, OS
62  2013 Impact on long-term OS of conditioning regimen in allogeneic BMT for children with AML in first CR: TBI+CY versus BU+CY: a report from the Société Française de Greffe de Moelle et de Thérapie Cellulaire. DFS
63  2013 In haematopoietic SCT for acute leukemia TBI impacts on relapse but not survival: results of a multicentre observational study. ---
64  2013 Incidence and risk factors for hypogammaglobulinemia in pediatric patients following allo-SCT. ---
65  2013 Interleukin-15 administration increases graft-versus-tumor activity in recipients of haploidentical hematopoietic SCT. GVT, HI, NK, TCD
66  2013 Late mortality after hematopoietic SCT for a childhood malignancy. ---
67  2013 Monitoring of TNFR1, IL-2Ralpha, HGF, CCL8, IL-8 and IL-12p70 following HSCT and their role as GVHD biomarkers in paediatric patients. HGF
68  2013 Outcomes of hematopoietic SCT recipients with rhinovirus infection: a matched, case-control study. ---
69  2013 Predictors of invasive fungal infection in pediatric allogeneic hematopoietic SCT recipients. IFI, OR, OR, TRM
70  2013 Retrospective study of alemtuzumab vs ATG-based conditioning without irradiation for unrelated and matched sibling donor transplants in acquired severe aplastic anemia: a study from the British Society for Blood and Marrow Transplantation. ATG, cGVHD, MSD, MUD, UD
71  2013 Risk factor analysis of idiopathic pneumonia syndrome after allogeneic hematopoietic SCT in children. IPS, IPS
72  2013 Risk factors for ICU admission and ICU survival after allogeneic hematopoietic SCT. ICU
73  2013 Salvage allogeneic hematopoietic SCT for primary graft failure in children. CBT, pGF
74  2013 Sicca symptoms and their impact on quality of life among very long-term survivors after hematopoietic SCT. QoL, SF, SFR
75  2013 Sjogren's syndrome associated chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) treated with autologous and subsequently allogeneic haematopoietic SCT (HSCT). CIDP
76  2013 Survey of CMV management in pediatric allogeneic HSCT programs, on behalf of the inborn errors, infectious diseases and pediatric diseases working parties of EBMT. ---
77  2013 The efficacy of selenium in prevention of oral mucositis in patients undergoing hematopoietic SCT: a randomized clinical trial. Glu.PX, HDC, OM
78  2013 The impact of morphological and immunohistological changes in minor salivary glands on the health of the oral cavity in HSCT patients. cGVHD, MSG, NIH
79  2013 The impact of T-cell depletion techniques on the outcome after haploidentical hematopoietic SCT. TCD
80  2012 5-day/5-drug myeloablative outpatient regimen for resistant neuroblastoma. NB, PD
81  2012 A novel protocol for haploidentical hematopoietic SCT without in vitro T-cell depletion in the treatment of severe acquired aplastic anemia. MMF, SAA, VSAA
82  2012 Allo-SCT using BU, CY and melphalan for children with AML in second CR. BuCyMel
83  2012 Anti-host isohemagglutinin production is associated with a higher risk of acute GVHD in ABO-incompatible transplantation. IH
84  2012 Attenuation of resting energy expenditure following hematopoietic SCT in children. PN, REE
85  2012 Bronchiolitis obliterans syndrome after allogeneic hematopoietic SCT: phenotypes and prognosis. BOS, FEV1, FVC, OLD
86  2012 Early evaluation of immune reconstitution following allogeneic CD3/CD19-depleted grafts from alternative donors in childhood acute leukemia. MUD, NK, RIC
87  2012 Efficacy of allogeneic and autologous hematopoietic SCT in patients with AML after first complete remission. allo-HSCT
88  2012 Evaluation of allogeneic hematopoietic SCT in younger adults with adverse karyotype AML. CIR, HR, RFS
89  2012 HHV-6 encephalitis in umbilical cord blood transplantation: a systematic review and meta-analysis. CB, HHV-6
90  2012 Higher angiopoietin-2 and VEGF levels predict shorter EFS and increased non-relapse mortality after pediatric hematopoietic SCT. aGVHD, Ang-2, NRM, VEGF
91  2012 Hyperbilirubinemia in the early phase after allogeneic HSCT: prognostic significance of the alkaline phosphatase/total bilirubin ratio. VOD/SOS
92  2012 Impact of viral reactivations in the era of pre-emptive antiviral drug therapy following allogeneic haematopoietic SCT in paediatric recipients. AdV, CMV
93  2012 Intravenous ribavirin for respiratory syncytial viral infections in pediatric hematopoietic SCT recipients. LRTI, RSV, URTI
94  2012 Juvenile metachromatic leukodystrophy 10 years post transplant compared with a non-transplanted cohort. MLD, MRI, MRS, NAA
95  2012 Long-term follow-up of informal caregivers after allo-SCT: a systematic review. allo-HSCT
96  2012 Long-term outcome of childhood aplastic anemia patients who underwent allogeneic hematopoietic SCT from an HLA-matched sibling donor in Japan. LM, SAA
97  2012 Low levels of 25-hydroxyvitamin D before allogeneic hematopoietic SCT correlate with the development of chronic GVHD. cGVHD, CI
98  2012 Management of adult patients older than 40 years refractory to at least one immunosuppressive course: HLA-identical sibling HSCT using fludarabine-based conditioning. ---
99  2012 Neoantigen and tumor antigen-specific immunity transferred from immunized donors is detectable early after allogeneic transplantation in myeloma patients. Id, KLH
100  2012 Outcome of children who experience disease relapse following allogeneic hematopoietic SCT for hematologic malignancies. DFS